An international legal framework to address antimicrobial resistance

Editorials 66 Antimicrobial resistance is recognized as a grave threat to global health. It already causes an estimated 700 000 deaths annually and – without effective action – is predicted to cause 10 million deaths annually by 2050. 3 The World Health Organization (WHO) has prepared a draft Global action plan on antimicrobial resistance that will be discussed at this year's World Health Assembly. 4 However, more is required if the world is to grapple effectively with this huge and complex problem. Global collective action is required in three areas: (i) access, to ensure that the prevention tools, diagnostics and therapies needed to reduce the infectious disease burden are available and affordable to everyone, everywhere; (ii) conservation, to reduce the need for antimicrobials and ensure their responsible use through prevention efforts, infection control, surveillance and appropriate prescriptions; and (iii) innovation , to develop the next generation of antimicrobials, vaccines, diagnostics and infection control technologies. The problem of antimicrobial resistance requires that all three areas be tackled simultaneously. Without conservation and innovation, universal access will simply drive resistance and deplete existing stocks of effective antimicrobials. Conservation, if pursued alone, will constrict the market for antimicrobials, restrict investment and innovation in the field and hinder access. 5 Innovation without conservation will waste new drugs and diminish the value of investments. Innovation without better access is inequitable. Like the legs of a tripod, each area needs the support of the other two. However, solving the issues of access, conservation and innovation simultaneously will require new coordination and financing mechanisms, some of which must be organized globally. To avert millions of deaths caused by treatable infections, access to antimicrobi-als should be scaled-up for the many people worldwide who cannot obtain or afford such drugs. Access could be facilitated by equitable pricing or licensing models, but external resources will be required to subsidize access for the world's poorest people. Such subsidies create common benefit, by reducing disease transmission and preventing reservoirs of resistant pathogens created by inconsistent use. Conservation activities should continue to be directed by national and local governments but global standards are needed for surveillance, infection control, health-worker training, sales promotion, direct-to-consumer advertising and safeguards against incentives for overuse. 6 Although public innovation funding will realistically continue to flow mostly from national budgets, stronger coordination is needed among key research funders and commercial investors in innovation. Some funding and rewards should also be …